5.13
-0.61 (-10.55%)
| Penutupan Terdahulu | 5.74 |
| Buka | 5.35 |
| Jumlah Dagangan | 236,946 |
| Purata Dagangan (3B) | 2,413,388 |
| Modal Pasaran | 7,658,372 |
| Harga / Jualan (P/S) | 1.27 |
| Harga / Buku (P/B) | 2.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Keuntungan | -43.80% |
| Margin Operasi (TTM) | -42.26% |
| EPS Cair (TTM) | -1.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 77.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 88.08% |
| Nisbah Semasa (MRQ) | 1.55 |
| Aliran Tunai Operasi (OCF TTM) | -3.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.26 M |
| Pulangan Atas Aset (ROA TTM) | -21.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -108.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Evoke Pharma, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.34% |
| % Dimiliki oleh Institusi | 16.23% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Aug 2025 | Pengumuman | Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book |
| 14 Aug 2025 | Pengumuman | Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 06 Aug 2025 | Pengumuman | Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 |
| 09 Jul 2025 | Pengumuman | Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |